Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 2562.

https://doi.org/10.1182/blood-2025-2562

Published: 2025

Journal Articles

Longitudinal biomarker dynamics for accurate risk prediction in 464 patients with asymptomatic IgM gammopathy: A spanish multicenter study

Blood (2025) 146 (Supplement 1): 2186.

https://doi.org/10.1182/blood-2025-2186

Published: 2025

Journal Articles

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta, Diego Alignani, Carmen Gonzalez, Noemi Puig, Elena Alejo, Jorge Labrador, Maria Casanova Espinosa, Laura Rosiñol Dachs, Sebastián Garzón, Enrique Ocio, Albert Pérez-Montaña, Irene Romera, Carmen Couto, Sunil Lakhwani, Felipe Prosper, Adrian Alegre, Elena Cabezudo, Itziar Carro, Cristina Motlló, Montserrat Cortes, Isabel Maria Garcia Cabrera, Marta Romera, Javier de la Rubia, Andrea Manubens, Alexia Suarez Cabrera, Fernando Escalante Barrigón, Carlos Aguilar-Franco, Raquel Del Campo, Maria Esther Clavero Sanchez, Joaquin Martinez-Lopez, Valentin Cabanas Perianes, María-Jesús Blanchard, Ana Lopez-Guia, Diana Sanchez Arguello, Albert Oriol, Marta Reinoso -Segura, María Lourdes Amador Barciela, Celina Benavente Cuesta, Jose Maria Arguiñano PEREZ, Beatriz Ordoñez, Francisco Taboada, Joan Batista Blade Creixenti, María-Victoria Mateos, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, Bruno Paiva

Blood (2025) 146 (Supplement 1): 578.

https://doi.org/10.1182/blood-2025-578

Published: 2025

Journal Articles

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

María-Jesús Blanchard, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Victoria Mateos, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2025-2272

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Talquetamab outcomes from practice outside of clinical trials: The bital study

María-Victoria Mateos, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Jesús Blanchard, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2025-5827

Published: 2025

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood (2024) 144 (23): 2432–2438.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Blood (2024) 144 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2024-205453

Published: 2024

Journal Articles

Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

Blood (2024) 144 (Supplement 1): 365.

https://doi.org/10.1182/blood-2024-209748

Published: 2024

Journal Articles

Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells

Beatriz Astibia Mahillo, María-Jesús Blanchard, Miguel Piris Villaespesa, Pablo Palomo Rumschisky, Jesús Villarrubia Espinosa, Valentín García Gutiérrez, Sr., Ana Jiménez, Mónica García-Cosío, Ernesto Roldán Santiago, Eulalia Rodríguez Martín, María Talavera Yagüez, Gemma Moreno Jiménez, Javier López, Fernando Martín Moro

Blood (2024) 144 (Supplement 1): 3349.

https://doi.org/10.1182/blood-2024-210589

Published: 2024

Journal Articles

GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Blood (2024) 144 (Supplement 1): 678.

https://doi.org/10.1182/blood-2024-203170

Published: 2024

Journal Articles

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Blood (2024) 144 (Supplement 1): 489.

https://doi.org/10.1182/blood-2024-210198

Published: 2024

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Blood (2023) 142 (Supplement 1): 3324.

https://doi.org/10.1182/blood-2023-184837

Published: 2023

Journal Articles

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 871.

https://doi.org/10.1182/blood-2023-185661

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Real-Life Experience of the Combination of Daratumumab, Bortezomib, Melphalan, and Prednisone (DVMP) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem-Cell Transplantation

Amalia Domingo-González, Rafael Alonso Fernández, Ana Jiménez, Teresa De Soto Alvarez, Ana Lerma, Virginia Pradillo Fernandez, Gonzalo Benzo Callejo, Jose Sanchez-Pina, Elena Landete, Alberto Velasco, Marina Menéndez Cuevas, Mónica María López Riñón, Andrés Ramírez López, Alberto Lopez Garcia, María-Jesús Blanchard, Elham Askari

Blood (2023) 142 (Supplement 1): 4745.

https://doi.org/10.1182/blood-2023-186954

Published: 2023

Journal Articles

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

Blood (2023) 142 (Supplement 1): 209.

https://doi.org/10.1182/blood-2023-179866

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Longitudinal biomarker dynamics for accurate risk prediction in 464 patients with asymptomatic IgM gammopathy: A spanish multicenter study

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Talquetamab outcomes from practice outside of clinical trials: The bital study

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial

Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells

GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Real-Life Experience of the Combination of Daratumumab, Bortezomib, Melphalan, and Prednisone (DVMP) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem-Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only